The WHO’s announcement came hours after Australia released a safety alert over the potential risk of suicidal thoughts and behaviours for people using the medicines.

A new study reported that Novo Nordisk spent $7.5 million over 2 years on more than 15,000 internet keywords — many focused on weight loss — that drove 2.4 million paid visits to its Ozempic.com ...

Canadian Prime Minister Mark Carney said he told Ontario’s premier not to run an anti-tariff advertisement that prompted US President Donald Trump to end trade talks with Canada. Carney also confirmed ...

Mounjaro reduces major heart problems by 8% versus Trulicity in trial Death from any cause was 16% lower for patients on Mounjaro versus Trulicity Safety profile similar for both drugs July 31 ...

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label expansions to reduce the risk of cardiovascular issues. But what about Eli ...

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations that it would do a better job of preventing heart attacks and strokes than its older medicine Trulicity.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s blockbuster ...

Trulicity (dulaglutide) is not a weight loss drug, but people receiving it may lose weight. Higher doses of Trulicity typically result in more weight loss. The FDA has not approved Trulicity as a ...

Google is getting sick and tired of YouTube watchers who use ad blockers, and — no surprise — the company is stepping it up in an effort to extract (reclaim?) even more ad revenue from users. On ...